{"id":5418,"date":"2021-12-23T11:57:04","date_gmt":"2021-12-23T08:57:04","guid":{"rendered":"https:\/\/www.klimik.org.tr\/koronavirus\/?p=5418"},"modified":"2021-12-24T11:59:50","modified_gmt":"2021-12-24T08:59:50","slug":"fda-belli-kriterlere-sahip-yetiskinlerde-covid-19-tedavisi-icin-bir-oral-antivirale-daha-izin-verdi","status":"publish","type":"post","link":"https:\/\/www.klimik.org.tr\/koronavirus\/fda-belli-kriterlere-sahip-yetiskinlerde-covid-19-tedavisi-icin-bir-oral-antivirale-daha-izin-verdi\/","title":{"rendered":"FDA, Belli Kriterlere Sahip Yeti\u015fkinlerde COVID-19 Tedavisi \u0130\u00e7in Bir Oral Antivirale Daha \u0130zin Verdi"},"content":{"rendered":"<p><img decoding=\"async\" loading=\"lazy\" class=\"wp-image-86785 alignleft\" src=\"https:\/\/www.klimik.org.tr\/wp-content\/uploads\/2020\/01\/FDA_.png\" alt=\"\" width=\"43\" height=\"43\" \/><strong>ABD G\u0131da ve \u0130la\u00e7 \u0130daresi (FDA), ba\u015fka alternatif yoksa 18 ya\u015f \u00fcst\u00fc belli kriterlere sahip yeti\u015fkinlerde COVID-19 tedavisi i\u00e7in Merck&#8217;in antiviral ilac\u0131 molnupiravire acil kullan\u0131m izni verdi.<\/strong><\/p>\n<p>FDA, SARS-CoV-2 testi pozitif olan, hastaneye yat\u0131\u015f veya \u00f6l\u00fcm dahil olmak \u00fczere \u015fiddetli COVID-19 ge\u00e7irme riski y\u00fcksek olan, FDA taraf\u0131ndan izin verilen alternatif COVID-19 tedavi se\u00e7eneklerine eri\u015filemeyen veya klinik olarak uygun olmayan yeti\u015fkinlerde hafif-orta \u015fiddette koronavirus hastal\u0131\u011f\u0131n\u0131n (COVID-19) tedavisi i\u00e7in Merck&#8217;in antiviral ilac\u0131 molnupiravire acil kullan\u0131m izni (EUA) yay\u0131mlad\u0131. Molnupiravir sadece re\u00e7eteyle al\u0131nabilir ve COVID-19 te\u015fhisi konulduktan sonra m\u00fcmk\u00fcn olan en k\u0131sa s\u00fcrede ve semptomlar\u0131n ba\u015flamas\u0131ndan sonraki be\u015f g\u00fcn i\u00e7inde ba\u015flanmal\u0131d\u0131r.<\/p>\n<p>Molnupiravir, kemik ve k\u0131k\u0131rdak b\u00fcy\u00fcmesini etkileyebilece\u011finden, 18 ya\u015f\u0131ndan k\u00fc\u00e7\u00fck hastalarda kullan\u0131lmas\u0131na izin verilmemi\u015ftir. COVID-19&#8217;un temas \u00f6ncesi veya temas sonras\u0131 \u00f6nlenmesinde ve COVID-19 nedeniyle hastaneye yat\u0131r\u0131lan hastalarda kullan\u0131m\u0131 i\u00e7in yetki verilmemi\u015ftir; \u00e7\u00fcnk\u00fc COVID-19 nedeniyle hastaneye yat\u0131r\u0131ld\u0131ktan sonra tedaviye ba\u015flanan ki\u015filerde faydas\u0131 g\u00f6r\u00fclmemi\u015ftir.<\/p>\n<p><strong><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain\">Haber \u0130\u00e7in T\u0131klay\u0131n\u0131z\u00a0<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ABD G\u0131da ve \u0130la\u00e7 \u0130daresi (FDA), ba\u015fka alternatif yoksa 18 ya\u015f \u00fcst\u00fc belli kriterlere sahip yeti\u015fkinlerde COVID-19 tedavisi i\u00e7in Merck&#8217;in antiviral ilac\u0131 molnupiravire acil kullan\u0131m izni verdi. FDA, SARS-CoV-2 testi pozitif olan, hastaneye yat\u0131\u015f veya \u00f6l\u00fcm dahil olmak \u00fczere \u015fiddetli COVID-19 ge\u00e7irme riski y\u00fcksek olan, FDA taraf\u0131ndan izin verilen alternatif COVID-19 tedavi se\u00e7eneklerine eri\u015filemeyen veya klinik olarak uygun olmayan yeti\u015fkinlerde hafif-orta \u015fiddette koronavirus hastal\u0131\u011f\u0131n\u0131n (COVID-19) tedavisi i\u00e7in Merck&#8217;in antiviral ilac\u0131 molnupiravire acil kullan\u0131m izni (EUA) yay\u0131mlad\u0131. Molnupiravir sadece re\u00e7eteyle al\u0131nabilir ve COVID-19 te\u015fhisi konulduktan sonra m\u00fcmk\u00fcn olan en k\u0131sa s\u00fcrede ve semptomlar\u0131n ba\u015flamas\u0131ndan sonraki be\u015f g\u00fcn i\u00e7inde ba\u015flanmal\u0131d\u0131r. Molnupiravir, kemik [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":5419,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5418"}],"collection":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/comments?post=5418"}],"version-history":[{"count":1,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5418\/revisions"}],"predecessor-version":[{"id":5420,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5418\/revisions\/5420"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media\/5419"}],"wp:attachment":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media?parent=5418"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/categories?post=5418"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/tags?post=5418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}